Adderall XR Cost in New York 2026: Cash Price, Insurance, and Compounding Options

What Is the Cash Price of Adderall XR in New York in 2026?

Generic mixed amphetamine salts XR costs approximately $30 per month at New York retail pharmacies when purchased with a discount card such as GoodRx or RxSaver. Without any discount, the same 30-capsule supply at a major New York chain can run $80 to $120 depending on the dose strength and the specific store. The Teva-branded version carries a manufacturer list price near $260 per month, though virtually no cash-paying patient actually pays that figure after applying a savings card or coupon.

Prices vary by dose. A 30-count supply of 10 mg generic capsules averages closer to $25 in New York City, while the 30 mg strength averages $35 to $40. Pharmacies in outer boroughs and upstate New York often price generics slightly lower than Manhattan chains because of different dispensing-fee structures. The FDA maintains a drug shortage database that tracked ongoing mixed amphetamine salts supply disruptions through 2023 and into 2024, which contributed to price volatility; checking that database before filling is worth doing if a particular dose strength is unavailable at your usual pharmacy. [1]

The Adderall XR FDA prescribing label confirms the approved dosage range for adults as 5 mg to 60 mg per day in one or two divided doses, though most adults are maintained on 10 mg to 30 mg once daily in the extended-release form. [2] Dose strength affects both availability and unit price, so patients maintained on lower doses often find better stock in New York pharmacies right now.

How Does New York Medicaid Cover Adderall XR?

New York Medicaid covers Adderall XR for both ADHD and narcolepsy indications, but a prior authorization (PA) is required before the claim will process. The PA criteria under New York State Medicaid align with the clinical standards published by the American Academy of Child and Adolescent Psychiatry: a confirmed ADHD diagnosis, documented prior trial of an immediate-release stimulant or clinical justification for starting with the extended-release form, and prescriber attestation of medical necessity. [3]

Once approved, the PA is typically valid for 12 months and renewable annually. Turnaround from submission to approval runs 24 to 72 hours at most managed-care organizations within the NY Medicaid system. Members enrolled in Medicaid Managed Care plans, such as Healthfirst, MetroPlus, or Fidelis Care, submit PAs through their respective plan portals rather than through the state fee-for-service system.

The New York State Department of Health Preferred Drug Program lists mixed amphetamine salts as a preferred drug when PA criteria are met, meaning the co-pay for Medicaid beneficiaries is effectively zero after approval. [4] Adults on Supplemental Security Income (SSI) Medicaid, the category that covers many patients with severe ADHD, pay no co-pay at all.

Patients who are denied should be aware of the New York State external appeal process: any Medicaid managed care denial can be appealed within 60 days, and external review is available through the New York State Department of Financial Services within 45 days of an internal appeal denial. [5]

Are Compounded Mixed Amphetamine Salts Legal in New York?

Compounded mixed amphetamine salts prepared by a state-licensed 503A pharmacy are legal to dispense in New York, provided the prescription meets federal and state requirements for compounding a Schedule II controlled substance. The critical legal distinction is that 503A pharmacies compound patient-specific prescriptions under the federal Drug Quality and Security Act, not commercial-scale bulk manufacturing. [6]

New York State requires a valid patient-specific prescription with a DEA-registered prescriber, and the compounding pharmacy must hold both a New York State Board of Pharmacy license and appropriate DEA Schedule II registration. [7] The New York State Board of Pharmacy conducts compliance inspections and has increased oversight of stimulant compounding since 2022 in response to telehealth-driven volume increases.

Cost is the main reason patients and providers ask about this pathway. Several telehealth platforms that operate in New York offer compounded mixed amphetamine salts at no additional drug cost (included in the subscription or visit fee), making the effective out-of-pocket drug cost $0 per month for the compounded product itself. The formulation is not bioequivalent-certified to brand Adderall XR, and the FDA has not approved any compounded version; the clinical decision to use a compounded product instead of an FDA-approved generic must involve a licensed prescriber. [8]

The MTA Cooperative Group study (N=579, Arch Gen Psychiatry 1999) established the efficacy benchmark for mixed amphetamine salts in children, demonstrating that combined behavioral and medication treatment produced ADHD symptom improvement in 68% of participants versus 34% with behavioral therapy alone. [9] That evidence base applies to FDA-approved formulations; compounded versions carry the caveat that potency and release characteristics have not been independently validated in controlled trials.

Which Commercial Insurance Plans Cover Adderall XR in New York?

Most major commercial plans offered in New York, including Empire BlueCross BlueShield, UnitedHealthcare, Aetna, Cigna, and MVP Health Care, cover generic mixed amphetamine salts on Tier 2 of their formularies. That means a typical co-pay of $10 to $45 per 30-day supply depending on plan design. Brand-name Adderall XR by Teva is usually placed on Tier 3 or Tier 4, with co-pays ranging from $50 to $100 or higher before the deductible is met. [10]

New York insurance law (New York Insurance Law §3221) requires all fully insured commercial plans that cover mental health benefits to comply with mental health parity under both the federal Mental Health Parity and Addiction Equity Act and state parity law. [11] ADHD medications prescribed for a diagnosed ADHD condition must receive the same prior authorization and coverage standards as medications for analogous medical conditions. A PA requirement for a stimulant that is not imposed on equivalent non-psychiatric medications may constitute a parity violation and can be challenged.

To determine exact Tier placement for your specific plan, check the plan's Summary of Benefits and Coverage or use the insurer's online formulary tool. Empire BlueCross plans through the NY State of Health marketplace generally place all generic mixed amphetamine salts on Tier 2 with no PA required for adults with a documented diagnosis. [12]

"Patients with ADHD who are insured but face formulary barriers should be counseled that parity law creates an explicit challenge mechanism," notes guidance from the American Academy of Pediatrics, which recommends that clinicians document parity violations and assist patients in filing complaints with their state insurance commissioner. [13]

What Is the Cheapest Way to Get Adderall XR in New York?

The cheapest path depends on insurance status.

For insured patients, verifying generic placement on Tier 1 or Tier 2 and avoiding brand-name dispense-as-written prescriptions is the first step. Generic mixed amphetamine salts XR at $10 to $20 co-pay beats any cash-pay discount card for most patients with commercial insurance.

For uninsured or underinsured patients, GoodRx and RxSaver discount cards reduce the retail cash price of generic mixed amphetamine salts XR to the $25 to $40 range at Costco, Walmart, Walgreens, and CVS locations across New York. [14] Costco pharmacies in New York consistently rank among the lowest-cost dispensers in the state for this drug class.

The Teva manufacturer savings card for branded Adderall XR is limited to commercially insured patients and generally caps out-of-pocket costs at $60 per month for eligible patients. Patients on any government-funded insurance, including Medicaid, Medicare, or CHIP, are explicitly excluded from manufacturer savings cards under federal anti-kickback rules. [15]

For uninsured New Yorkers below 200% of the federal poverty level, the New York State Pharmaceutical Assistance Program (EPIC for seniors, ADAP for others) and patient assistance programs through Teva may reduce costs further. Teva's patient assistance program provides brand Adderall XR at no cost for patients meeting income criteria. [16]

Telehealth platforms offering compounded mixed amphetamine salts with $0 drug cost represent the lowest total out-of-pocket option for some uninsured patients, though the monthly platform fee (typically $99 to $199) must be factored into the true cost comparison.

Can a New York Patient Get Adderall XR via Telehealth?

Telehealth prescribing of Adderall XR is legal in New York for patients who meet federal and state requirements. Under the federal Ryan Haight Act, prescribing Schedule II controlled substances via telemedicine required an in-person evaluation until the DEA issued special telehealth registrations in 2023. [17] As of 2025, DEA-registered telehealth providers who hold a Special Registration for Telemedicine can prescribe Schedule II stimulants without a prior in-person visit, provided the prescriber conducts a synchronous audio-video evaluation and the patient is located in a state where the prescriber holds an active license. New York participates in the Interstate Medical Licensure Compact, which simplifies multi-state prescribing.

New York State Public Health Law also requires that telehealth encounters for controlled substances include a real-time video component; audio-only prescribing of Schedule II drugs is not permitted. [18] The prescriber must document a complete psychiatric and medical history, rule out contraindications (including cardiovascular disease, hypertension, and a history of stimulant misuse), and establish a valid prescriber-patient relationship before issuing any stimulant prescription.

Platforms operating legally in New York as of 2025 include Done Health, Cerebral (following its 2023 compliance reforms), Ahead, and Teladoc Mental Health, each with different pricing structures and formularies. Patients should confirm that the specific platform holds current DEA telehealth registration and that prescribers hold active New York licenses before enrolling.

How Does the Adderall XR Shortage Affect New York Prices and Access in 2026?

The FDA declared the Adderall shortage in October 2022 following a manufacturing slowdown at Teva's main U.S. facility. [19] Supply has partially recovered through 2024 and into 2025, with multiple generic manufacturers (Lannett, Mallinckrodt, Amneal, and others) now producing mixed amphetamine salts XR. However, specific dose strengths, particularly 20 mg and 30 mg XR capsules, still face intermittent stockouts at individual New York pharmacies.

The practical effect on pricing has been modest for most dose strengths. Generic competition from at least four manufacturers has kept the cash price competitive near the $30 mean. The shortage's main impact in New York has been access-related rather than price-related: patients are sometimes forced to call multiple pharmacies to locate stock, or to split fills across two pharmacies. New York State law allows partial fills of Schedule II prescriptions if the full quantity is unavailable, with the remainder dispensed within 30 days of the original prescription date. [20]

Pharmacists at independent New York pharmacies report that maintaining relationships with multiple wholesalers (AmerisourceBergen, McKesson, and Cardinal Health) improves their ability to source mixed amphetamine salts reliably. Patients who experience repeated stockouts should ask their prescriber to authorize switching between equivalent generic manufacturers or to consider dose-strength adjustments that may be better stocked locally.

Clinical Context: Who Qualifies for Adderall XR in New York?

Adderall XR (mixed amphetamine salts, extended-release) is FDA-approved for ADHD in patients age 6 and older, and for narcolepsy. [2] New York prescribers follow the American Psychiatric Association DSM-5 criteria for ADHD diagnosis, requiring symptom onset before age 12, symptoms present in two or more settings, and clinically significant functional impairment. [21]

The Multimodal Treatment Study of Children with ADHD (MTA, N=579) remains the most cited long-term randomized controlled trial in this area. At 14 months, medication management alone produced greater reductions in ADHD core symptoms than behavioral treatment alone (mean symptom reduction score 3.6 vs. 2.5, P<0.001). [9] The combination of medication and behavioral therapy produced outcomes statistically comparable to medication alone on core symptoms but showed advantages on secondary outcomes including anxiety, academic achievement, and parent-child relations.

Adults with ADHD in New York are also commonly treated with Adderall XR. A 2020 meta-analysis in The Lancet Psychiatry (N=11,018 across 81 trials) found that amphetamines produced the largest effect size for adult ADHD symptom reduction among all stimulant and non-stimulant options studied, with a standardized mean difference of 0.79 (95% CI 0.63 to 0.95) versus placebo. [22] New York prescribers are required to assess cardiovascular risk before initiating stimulant therapy; the American Heart Association recommends an ECG for patients with known cardiac risk factors prior to stimulant initiation. [23]

Patients with a history of substance use disorder require particular evaluation. The New York Office of Addiction Services and Supports (OASAS) does not prohibit stimulant prescribing for comorbid ADHD and substance use disorder but recommends close monitoring and, where possible, prescribing in coordination with addiction medicine specialists. [24]

New York-Specific Savings Programs and Assistance Options

New York State runs several programs that can reduce stimulant medication costs beyond federal options.

The Elderly Pharmaceutical Insurance Coverage (EPIC) program, administered by the New York State Department of Health, helps New Yorkers age 65 and older with prescription costs. EPIC members who are not on Medicare Part D can use EPIC as primary payer for generic Adderall XR. [25] For members enrolled in both EPIC and Medicare Part D, EPIC supplements Part D by covering co-pays and deductibles.

The New York State Child Health Plus program, which covers children and adolescents up to age 19, covers Adderall XR for ADHD with a co-pay of $3 per prescription for families at or below 160% of the federal poverty level. [26]

The 340B Drug Pricing Program, a federal program that allows qualifying health centers to purchase drugs at significantly reduced prices, applies to many Federally Qualified Health Centers (FQHCs) across New York City and upstate. Patients who receive care at a 340B-covered entity may pay substantially less for stimulant medications when dispensed through the entity's in-house or contract pharmacy. [27]

New York City's public health system (NYC Health + Hospitals) operates 11 hospital-based ambulatory care sites that provide psychiatric services, including ADHD treatment, on a sliding-scale fee basis. Medication costs for uninsured patients at these sites are often processed through 340B pricing. [28]

"Clinicians caring for patients with ADHD should be aware of the range of financing programs available in their state, as cost is among the most frequently cited barriers to medication adherence," states the American Academy of Pediatrics Clinical Practice Guideline for Diagnosis, Evaluation, and Treatment of ADHD. [13]